Tricida, Inc.
TCDA
$0.00
Change (1 day)
$13.85
Year High
$0.04
Year Low
Categories
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Revenue of Tricida, Inc. (TCDA)
Revenue in 2021 (TTM): $
According to Tricida, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Tricida, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2021 | $ | $ | $-158,522,000 | $-176,566,000 | $-194,168,000 |
| 2020 | $ | $ | $-245,487,000 | $-264,791,000 | $-264,791,000 |
| 2019 | $ | $ | $-169,440,000 | $-176,905,000 | $-176,813,000 |
| 2018 | $ | $ | $-102,190,000 | $-102,808,000 | $-102,808,000 |
| 2017 | $ | $ | $-40,955,000 | $-41,290,000 | $-41,290,000 |
| 2016 | $ | $ | $-28,227,000 | $-28,651,000 | $-28,651,000 |